Mechanism of Ceftriaxone Induction of Excitatory Amino Acid Transporter-2 Expression and Glutamate Uptake in Primary Human Astrocytes

Glutamate is an essential neurotransmitter regulating brain functions. Excitatory amino acid transporter (EAAT)-2 is one of the major glutamate transporters primarily expressed in astroglial cells. Dysfunction of EAAT2 is implicated in acute and chronic neurological disorders, including stroke/ischemia, temporal lobe epilepsy, amyotrophic lateral sclerosis, Alzheimer disease, human immunodeficiency virus 1-associated dementia, and growth of malignant gliomas. Ceftriaxone, one of the β-lactam antibiotics, is a stimulator of EAAT2 expression with neuroprotective effects in both in vitro and in vivo models based in part on its ability to inhibit neuronal cell death by glutamate excitotoxicity. Based on this consideration and its lack of toxicity, ceftriaxone has potential to manipulate glutamate transmission and ameliorate neurotoxicity. We investigated the mechanism by which ceftriaxone enhances EAAT2 expression in primary human fetal astrocytes (PHFA). Ceftriaxone elevated EAAT2 transcription in PHFA through the nuclear factor-κB (NF-κB) signaling pathway. The antibiotic promoted nuclear translocation of p65 and activation of NF-κB. The specific NF-κB binding site at the -272 position of the EAAT2 promoter was responsible for ceftriaxone-mediated EAAT2 induction. In addition, ceftriaxone increased glutamate uptake, a primary function of EAAT2, and EAAT2 small interference RNA completely inhibited ceftriaxone-induced glutamate uptake activity in PHFA. Taken together, our data ceftriaxone is a of glutamate in PHFA through EAAT2 promoter a mechanism for ceftriaxone of glutamate and for its potential effects on specific through of Glutamate is an essential neurotransmitter regulating brain functions. Excitatory amino acid transporter (EAAT)-2 is one of the major glutamate transporters primarily expressed in astroglial cells. Dysfunction of EAAT2 is implicated in acute and chronic neurological disorders, including stroke/ischemia, temporal lobe epilepsy, amyotrophic lateral sclerosis, Alzheimer disease, human immunodeficiency virus 1-associated dementia, and growth of malignant gliomas. Ceftriaxone, one of the β-lactam antibiotics, is a stimulator of EAAT2 expression with neuroprotective effects in both in vitro and in vivo models based in part on its ability to inhibit neuronal cell death by glutamate excitotoxicity. Based on this consideration and its lack of toxicity, ceftriaxone has potential to manipulate glutamate transmission and ameliorate neurotoxicity. We investigated the mechanism by which ceftriaxone enhances EAAT2 expression in primary human fetal astrocytes (PHFA). Ceftriaxone elevated EAAT2 transcription in PHFA through the nuclear factor-κB (NF-κB) signaling pathway. The antibiotic promoted nuclear translocation of p65 and activation of NF-κB. The specific NF-κB binding site at the -272 position of the EAAT2 promoter was responsible for ceftriaxone-mediated EAAT2 induction. In addition, ceftriaxone increased glutamate uptake, a primary function of EAAT2, and EAAT2 small interference RNA completely inhibited ceftriaxone-induced glutamate uptake activity in PHFA. Taken together, our data ceftriaxone is a of glutamate in PHFA through EAAT2 promoter a mechanism for ceftriaxone of glutamate and for its potential effects on specific through of Glutamate a in brain and is the major of in the and is implicated in of brain including and Glutamate its signaling by on glutamate on the of cells. is the glutamate in the the of is the glutamate is at a activation of glutamate is and glutamate is a at The brain of a small of this glutamate is in the Glutamate is and is the Glutamate amino acid this of glutamate the amino acid transporter amino acid primary human fetal nuclear glutamate human immunodeficiency amino acid small interference amino acid primary human fetal nuclear glutamate human immunodeficiency amino acid small interference and The glutamate transporters in the brain and EAAT2, in the transporter and glutamate which primarily expressed in astrocytes in glutamate implicated in the of neurological of EAAT2 by of glutamate in the and neuronal death in neurological of including amyotrophic lateral Alzheimer of brain human immunodeficiency virus and of primary human fetal astrocytes in of both EAAT2 and and glutamate uptake in In a with which both EAAT2 and and glutamate uptake in an of glutamate in the of on the of glutamate by astrocytes in brain and and for β-lactam of and to inhibit The of The β-lactam ceftriaxone both brain expression of EAAT2 and its and activity in vivo and is neuroprotective in vitro in models of and based in part on glutamate of increased and in an of amyotrophic lateral this to through increased transcription of the EAAT2 the by which enhances EAAT2 expression In this the mechanism of EAAT2 expression and glutamate in and human fetal brain in with of PHFA and activation NF-κB and NF-κB the in for at with and The was of the human EAAT2 promoter with by the The was the in the of the to the The of The The and p65 expression EAAT2 and p65 of and cell and was and nuclear to the The and EAAT2 the of and EAAT2, The was for p65 and The for and and expression was of to and RNA was the to the of RNA was for The and nuclear and of in and with of and to the activity was by and the data the activation at in to the was The of -272 and The of the -272 a NF-κB binding site at the -272 position of the EAAT2 promoter The is of was to the and was for at the of with at and with the with in was with and with with a in at in to and at in and to with to glutamate uptake The expressed in expressed of at The was for was EAAT2 by in and EAAT2 expression in the of on and EAAT2 was in of PHFA with EAAT2 on expression in PHFA data expression in the EAAT2 was with an in RNA PHFA with was and by in EAAT2 was increased in PHFA. was by transcription by nuclear human EAAT2 expression is by at a in the EAAT2 the human EAAT2 an EAAT2 was PHFA in for at EAAT2 promoter activity in a to a of the EAAT2 promoter to this β-lactam We in the in the EAAT2 promoter essential for to of of the EAAT2 and the with The promoter activity of and in a NF-κB binding in the of the EAAT2 promoter for the promoter activity In addition, to in a of promoter activity transcription binding to the of regulating of the EAAT2 promoter in to the EAAT2 PHFA with the with a an with of for activity to of the PHFA with EAAT2 promoter with an with for activity to of the in for EAAT2 NF-κB a in and of the EAAT2 promoter NF-κB is a of the EAAT2 promoter activation by NF-κB and The of NF-κB and inhibited EAAT2 promoter activation with in EAAT2 promoter activity in PHFA NF-κB is in EAAT2 promoter is for EAAT2 PHFA with The PHFA and with with an with with the for activity to of the in cells. PHFA with for and nuclear with the NF-κB binding site at of the EAAT2 promoter and nuclear and nuclear a of the NF-κB site was was with an The and NF-κB and a PHFA with the with an with for activity to of the in at the -272 of the EAAT2 to the human EAAT2 promoter is by and the NF-κB signaling this EAAT2 promoter NF-κB binding in the of the EAAT2 promoter and the one is at the position of the EAAT2 promoter which is responsible for this NF-κB binding site the and position of the EAAT2 in the of by the and the NF-κB binding at the and in with PHFA nuclear the of one by the -272 the NF-κB binding site at the -272 position of the EAAT2 was in nuclear with nuclear this increased PHFA nuclear an -272 and a -272 in the -272 NF-κB binding site in in completely the increased In the -272 on the NF-κB binding site at the -272 position of the EAAT2 promoter the transcription with in a of the by the of a of NF-κB in the Taken together, data binding of NF-κB to the -272 NF-κB binding site in the EAAT2 the of the -272 NF-κB binding site of the EAAT2 a EAAT2 a in the -272 NF-κB binding site was was and the with in the to In addition, the of the -272 NF-κB binding site the EAAT2 promoter NF-κB for the activity of the EAAT2 promoter the NF-κB binding site at the -272 position is for EAAT2 promoter activity EAAT2 promoter NF-κB and p65 NF-κB is through the of the binding to the NF-κB The of which to the to expression of NF-κB activation through a the expression of and the p65 of NF-κB by in the of in of PHFA was with the of p65 was in the and increased in the nuclear of PHFA In and nuclear in in the increased in PHFA In addition, inhibited p65 nuclear translocation the translocation of p65 the to the in NF-κB the activity of a NF-κB binding in the activity of and a of NF-κB the of p65 in EAAT2 promoter investigated p65 p65 EAAT2 promoter in p65 the EAAT2 promoter and the EAAT2 promoter activation In addition, p65 EAAT2 promoter activation The activity of p65 was by p65 in NF-κB activation through of the p65 nuclear translocation and the expression of its including NF-κB. PHFA with for and and with the and the for and PHFA with and with for The p65 and by PHFA with The with NF-κB binding with an the with for activity to of in with PHFA with the and p65 expression with a an with for activity to of the and PHFA with the and p65 with a an with for activity to of the and The cell with and p65 for Glutamate in Glutamate transporters to astroglial in increased expression is by and activity Based on this investigated EAAT2 expression the activity of EAAT2 a glutamate in increased in and this increased glutamate transporter activity was inhibited by EAAT2 and EAAT2 glutamate uptake in PHFA The activity of and EAAT2 was by and EAAT2 expression in In addition, of NF-κB completely the of glutamate uptake activity glutamate transporter activity in PHFA by of EAAT2 expression through the NF-κB signaling glutamate uptake in PHFA. PHFA with EAAT2 and the with glutamate uptake cell PHFA with EAAT2 and and EAAT2 PHFA with and the with glutamate uptake is implicated in including amyotrophic lateral sclerosis, disease, Alzheimer disease, epilepsy, dementia, and in the mechanism by which astrocytes glutamate and glutamate to to astrocytes neuronal function is through the EAAT2 transporter and its to of in the to in this in the of glutamate in and death of in the of glutamate is to the of EAAT2 expression in astrocytes and of this in expression and activity of EAAT2 by responsible for the of glutamate uptake in amyotrophic lateral one of the β-lactam and a was neuroprotective in vitro and in vivo and its for EAAT2 expression was which is with the with for β-lactam potential In the the mechanism by which EAAT2 a expression in the in the expression of EAAT2, in EAAT2 expression in human astrocytes in EAAT2 expression at the and and data β-lactam and EAAT2 expression at the The and our the cell and primary and with and the PHFA and β-lactam EAAT2 and expressed in amino acid of human is expressed in In the of the a neuronal transporter glutamate and activation of of signaling and expression data expression of EAAT2, and is a transcription a in regulating a of in cell growth and and in NF-κB the EAAT2 activation of the NF-κB signaling this In the NF-κB is expressed in and in with in to regulating NF-κB has a expression of in the brain in the of glutamate the EAAT2 promoter has NF-κB binding for and of EAAT2 expression one NF-κB binding site at the -272 position of the EAAT2 promoter is responsible for the EAAT2 promoter activation and EAAT2 promoter is on and NF-κB EAAT2 transcription through signaling in with transcription NF-κB binding site in the EAAT2 promoter is responsible for of signaling through NF-κB with We the NF-κB signaling p65 nuclear translocation through the of which EAAT2 promoter activation and of glutamate uptake in PHFA In our data is a of glutamate through EAAT2 In addition, in and by and and neuronal cell death by through activation of EAAT2 a to brain the of to Taken together, and in a this a for and a of by glutamate excitotoxicity. Glutamate a in brain and is the major of in the and is implicated in of brain including and Glutamate its signaling by on glutamate on the of cells. is the glutamate in the the of is the glutamate is at a activation of glutamate is and glutamate is a at The brain of a small of this glutamate is in the Glutamate is and is the Glutamate amino acid this of glutamate the amino acid transporter amino acid primary human fetal nuclear glutamate human immunodeficiency amino acid small interference amino acid primary human fetal nuclear glutamate human immunodeficiency amino acid small interference and The glutamate transporters in the brain and EAAT2, in the transporter and glutamate which primarily expressed in astrocytes in glutamate implicated in the of neurological of EAAT2 by of glutamate in the and neuronal death in neurological of including amyotrophic lateral Alzheimer of brain human immunodeficiency virus and of primary human fetal astrocytes in of both EAAT2 and and glutamate uptake in In a with which both EAAT2 and and glutamate uptake in an of glutamate in the of Based on the of glutamate by astrocytes in brain and and for β-lactam of and to inhibit The of The β-lactam ceftriaxone both brain expression of EAAT2 and its and activity in vivo and is neuroprotective in vitro in models of and based in part on glutamate of increased and in an of amyotrophic lateral this to through increased transcription of the EAAT2 the by which enhances EAAT2 expression In this the mechanism of EAAT2 expression and glutamate in PHFA. and human fetal brain in with of PHFA and activation NF-κB and NF-κB the in for at with and The was of the human EAAT2 promoter with by the The was the in the of the to the The of The The and p65 expression EAAT2 and p65 of and cell and was and nuclear to the The and EAAT2 the of and EAAT2, The was for p65 and The for and and expression was of to and RNA was the to the of RNA was for The and nuclear and of in and with of and to the activity was by and the data the activation at in to the was The of -272 and The of the -272 a NF-κB binding site at the -272 position of the EAAT2 promoter The is of was to the and was for at the of with at and with the with in was with and with with a in at in to and at in and to with to glutamate uptake The expressed in expressed of at The was for was and human fetal brain in with of PHFA and activation NF-κB and NF-κB the in for at with and The was of the human EAAT2 promoter with by the The was the in the of the to the The of The The and p65 expression EAAT2 and p65 of and cell and was and nuclear to the The and EAAT2 the of and EAAT2, The was for p65 and The for and and expression was of to and RNA was the to the of RNA was for The and nuclear and of in and with of and to the activity was by and the data the activation at in to the was The of -272 and The of the -272 a NF-κB binding site at the -272 position of the EAAT2 promoter The is of was to the and was for at the of with at and with the with in was with and with with a Glutamate in at in to and at in and to with to glutamate uptake The expressed in expressed of at The was for was EAAT2 by in and EAAT2 expression in the of on and EAAT2 was in of PHFA with EAAT2 on expression in PHFA data expression in the EAAT2 was with an in RNA PHFA with was and by in EAAT2 was increased in PHFA. was by transcription by nuclear human EAAT2 expression is by at a in the EAAT2 the human EAAT2 an EAAT2 was PHFA in for at EAAT2 promoter activity in a to a of the EAAT2 promoter to this β-lactam We in the in the EAAT2 promoter essential for to of of the EAAT2 and the with The promoter activity of and in a NF-κB binding in the of the EAAT2 promoter for the promoter activity In addition, to in a of promoter activity transcription binding to the of regulating of the EAAT2 promoter in to for EAAT2 NF-κB a in and of the EAAT2 promoter NF-κB is a of the EAAT2 promoter activation by NF-κB and The of NF-κB and inhibited EAAT2 promoter activation with in EAAT2 promoter activity in PHFA NF-κB is in EAAT2 promoter is for EAAT2 PHFA with The PHFA and with with an with with the for activity to of the in cells. PHFA with for and nuclear with the NF-κB binding site at of the EAAT2 promoter and nuclear and nuclear a of the NF-κB site was was with an The and NF-κB and a PHFA with the with an with for activity to of the in at the -272 of the EAAT2 to the human EAAT2 promoter is by and the NF-κB signaling this EAAT2 promoter NF-κB binding in the of the EAAT2 promoter and the one is at the position of the EAAT2 promoter which is responsible for this NF-κB binding site the and position of the EAAT2 in the of by the and the NF-κB binding at the and in with PHFA nuclear the of one by the -272 the NF-κB binding site at the -272 position of the EAAT2 was in nuclear with nuclear this increased PHFA nuclear an -272 and a -272 in the -272 NF-κB binding site in in completely the increased In the -272 on the NF-κB binding site at the -272 position of the EAAT2 promoter the transcription with in a of the by the of a of NF-κB in the Taken together, data binding of NF-κB to the -272 NF-κB binding site in the EAAT2 the of the -272 NF-κB binding site of the EAAT2 a EAAT2 a in the -272 NF-κB binding site was was and the with in the to In addition, the of the -272 NF-κB binding site the EAAT2 promoter NF-κB for the activity of the EAAT2 promoter the NF-κB binding site at the -272 position is for EAAT2 promoter activity EAAT2 promoter NF-κB and p65 NF-κB is through the of the binding to the NF-κB The of which to the to expression of NF-κB activation through a the expression of and the p65 of NF-κB by in the of in of PHFA was with the of p65 was in the and increased in the nuclear of PHFA In and nuclear in in the increased in PHFA In addition, inhibited p65 nuclear translocation the translocation of p65 the to the in NF-κB the activity of a NF-κB binding in the activity of and a of NF-κB the of p65 in EAAT2 promoter investigated p65 p65 EAAT2 promoter in p65 the EAAT2 promoter and the EAAT2 promoter activation In addition, p65 EAAT2 promoter activation The activity of p65 was by p65 in NF-κB activation through of the p65 nuclear translocation and the expression of its including NF-κB. PHFA with for and and with the and the for and PHFA with and with for The p65 and by PHFA with The with NF-κB binding with an the with for activity to of in with PHFA with the and p65 expression with a an with for activity to of the and PHFA with the and p65 with a an with for activity to of the and The cell with and p65 for Glutamate in Glutamate transporters to astroglial in increased expression is by and activity Based on this investigated EAAT2 expression the activity of EAAT2 a glutamate in increased in and this increased glutamate transporter activity was inhibited by EAAT2 and EAAT2 glutamate uptake in PHFA The activity of and EAAT2 was by and EAAT2 expression in In addition, of NF-κB completely the of glutamate uptake activity glutamate transporter activity in PHFA by of EAAT2 expression through the NF-κB signaling glutamate uptake in PHFA. PHFA with EAAT2 and the with glutamate uptake cell PHFA with EAAT2 and and EAAT2 PHFA with and the with glutamate uptake EAAT2 by in and EAAT2 expression in the of on and EAAT2 was in of PHFA with EAAT2 on expression in PHFA data expression in the EAAT2 was with an in RNA PHFA with was and by in EAAT2 was increased in PHFA. was by transcription by nuclear human EAAT2 expression is by at a in PHFA. the EAAT2 the human EAAT2 an EAAT2 was PHFA in for at EAAT2 promoter activity in a to a of the EAAT2 promoter to this β-lactam We in the in the EAAT2 promoter essential for to of of the EAAT2 and the with The promoter activity of and in a NF-κB binding in the of the EAAT2 promoter for the promoter activity In addition, to in a of promoter activity transcription binding to the of regulating of the EAAT2 promoter in to NF-κB for EAAT2 NF-κB a in and of the EAAT2 promoter NF-κB is a of the EAAT2 promoter activation by NF-κB and The of NF-κB and inhibited EAAT2 promoter activation with in EAAT2 promoter activity in PHFA NF-κB is in EAAT2 promoter NF-κB at the -272 of the EAAT2 to the human EAAT2 promoter is by and the NF-κB signaling this EAAT2 promoter NF-κB binding in the of the EAAT2 promoter and the one is at the position of the EAAT2 promoter which is responsible for this NF-κB binding site the and position of the EAAT2 in the of by the and the NF-κB binding at the and in with PHFA nuclear the of one by the -272 the NF-κB binding site at the -272 position of the EAAT2 was in nuclear with nuclear this increased PHFA nuclear an -272 and a -272 in the -272 NF-κB binding site in in completely the increased In the -272 on the NF-κB binding site at the -272 position of the EAAT2 promoter the transcription with in a of the by the of a of NF-κB in the Taken together, data binding of NF-κB to the -272 NF-κB binding site in the EAAT2 the of the -272 NF-κB binding site of the EAAT2 a EAAT2 a in the -272 NF-κB binding site was was and the with in the to In addition, the of the -272 NF-κB binding site the EAAT2 promoter NF-κB for the activity of the EAAT2 promoter the NF-κB binding site at the -272 position is for EAAT2 promoter activity EAAT2 promoter NF-κB and p65 NF-κB is through the of the binding to the NF-κB The of which to the to expression of NF-κB activation through a the expression of and the p65 of NF-κB by in the of in of PHFA was with the of p65 was in the and increased in the nuclear of PHFA In and nuclear in in the increased in PHFA In addition, inhibited p65 nuclear translocation the translocation of p65 the to the in NF-κB the activity of a NF-κB binding in the activity of and a of NF-κB the of p65 in EAAT2 promoter investigated p65 p65 EAAT2 promoter in p65 the EAAT2 promoter and the EAAT2 promoter activation In addition, p65 EAAT2 promoter activation The activity of p65 was by p65 in NF-κB activation through of the p65 nuclear translocation and the expression of its including Glutamate in Glutamate transporters to astroglial in increased expression is by and activity Based on this investigated EAAT2 expression the activity of EAAT2 a glutamate in increased in and this increased glutamate transporter activity was inhibited by EAAT2 and EAAT2 glutamate uptake in PHFA The activity of and EAAT2 was by and EAAT2 expression in In addition, of NF-κB completely the of glutamate uptake activity glutamate transporter activity in PHFA by of EAAT2 expression through the NF-κB signaling pathway. is implicated in including amyotrophic lateral sclerosis, disease, Alzheimer disease, epilepsy, dementia, and in the mechanism by which astrocytes glutamate and glutamate to to astrocytes neuronal function is through the EAAT2 transporter and its to of in the to in this in the of glutamate in and death of in the of glutamate is to the of EAAT2 expression in astrocytes and of this in expression and activity of EAAT2 by responsible for the of glutamate uptake in amyotrophic lateral one of the β-lactam and a was neuroprotective in vitro and in vivo and its for EAAT2 expression was which is with the with for β-lactam potential In the the mechanism by which EAAT2 a expression in the in the expression of EAAT2, in EAAT2 expression in human astrocytes in EAAT2 expression at the and and data β-lactam and EAAT2 expression at the The and our the cell and primary and with and the PHFA and β-lactam EAAT2 and expressed in amino acid of human is expressed in In the of the a neuronal transporter glutamate and activation of of signaling and expression data expression of EAAT2, and is a transcription a in regulating a of in cell growth and and in NF-κB the EAAT2 activation of the NF-κB signaling this In the NF-κB is expressed in and in with in to regulating NF-κB has a expression of in the brain in the of glutamate the EAAT2 promoter has NF-κB binding for and of EAAT2 expression one NF-κB binding site at the -272 position of the EAAT2 promoter is responsible for the EAAT2 promoter activation and EAAT2 promoter is on and NF-κB EAAT2 transcription through signaling in with transcription NF-κB binding site in the EAAT2 promoter is responsible for of signaling through NF-κB with We the NF-κB signaling p65 nuclear translocation through the of which EAAT2 promoter activation and of glutamate uptake in PHFA In our data is a of glutamate through EAAT2 In addition, in and by and and neuronal cell death by through activation of EAAT2 a to brain the of to Taken together, and in a this a for and a of by glutamate excitotoxicity. Glutamate is implicated in including amyotrophic lateral sclerosis, disease, Alzheimer disease, epilepsy, dementia, and in the mechanism by which astrocytes glutamate and glutamate to to astrocytes neuronal function is through the EAAT2 transporter and its to of in the to in this in the of glutamate in and death of in the of glutamate is to the of EAAT2 expression in astrocytes and of this in expression and activity of EAAT2 by responsible for the of glutamate uptake in amyotrophic lateral one of the β-lactam and a was neuroprotective in vitro and in vivo and its for EAAT2 expression was which is with the with for β-lactam potential In the the mechanism by which EAAT2 In a expression in the in the expression of EAAT2, in EAAT2 expression in human astrocytes in EAAT2 expression at the and and data β-lactam and EAAT2 expression at the The and our the cell and primary and with and the PHFA and β-lactam EAAT2 and expressed in amino acid of human is expressed in In the of the a neuronal transporter glutamate and activation of of signaling and expression data expression of EAAT2, and NF-κB is a transcription a in regulating a of in cell growth and and in NF-κB the EAAT2 activation of the NF-κB signaling this In the NF-κB is expressed in and in with in to regulating NF-κB has a expression of in the brain in the of glutamate the EAAT2 promoter has NF-κB binding for and of EAAT2 expression one NF-κB binding site at the -272 position of the EAAT2 promoter is responsible for the EAAT2 promoter activation and EAAT2 promoter is on and NF-κB EAAT2 transcription through signaling in with transcription NF-κB binding site in the EAAT2 promoter is responsible for of signaling through NF-κB with We the NF-κB signaling p65 nuclear translocation through the of which EAAT2 promoter activation and of glutamate uptake in PHFA In our data is a of glutamate through EAAT2 In addition, in and by and and neuronal cell death by through activation of EAAT2 a to brain the of to Taken together, and in a this a for and a of by glutamate excitotoxicity.